Saturday 17 October 2026
Export DFTX’s income statement to Excel — free account
Definium Therapeutics, Inc.
DFTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 188.0%, free cash flow fell 78.3% and total debt fell 11.5%, each against the same quarter a year earlier.
32.10
2.16
−6.30%
Follow DFTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(85.59%) | (64.06%) | (94.70%) | (64.09%) | |
| (60.39%) | (49.52%) | (70.22%) | (51.35%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(111.74%) | (52.12%) | (79.33%) | (37.84%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.33) | (1.47) | (1.33) | (1.52) | |
Free Cash Flow |
(113.94) | (131.56) | (144.77) | (167.95) | |
| Other line items | |||||
Cash ROIC |
(29.98%) | (16.77%) | (20.89%) | (8.24%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(31.05) | (30.34) | (31.57) | (45.33) | |
Operating CF/Net income |
0.68 | 0.72 | 0.61 | 0.47 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.33) | (1.47) | (1.33) | (1.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates